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CHAPTER-I 
INTRODUCTION 
During the past decade, advanced drug delivery research and development has 
surged. The emergence of nanotechnology and the growing capabilities of proteomics, 
genomics and combinatorial chemistry have provided scientists with new technologies.  
Commonly accepted criteria of advanced drug delivery system include [1]: 
a) maximal drug bioavailability  
b) tissue targeting 
c) controlled release kinetics  
d) minimal immune response  
e) ease of administration for patient compliance  
f) ability to delivery different drug such as lipophiles, amphiphiles and 
biomolecules.   
A drug’s therapeutic efficacy depends on four fundamental pathways of drug 
transport and modification within the body: 
• absorption into the plasma form the administration site. 
• distribution between plasma and tissues. 
• metabolism within the tissues. 
• elimination from the body. 
Absorption rate depends on many factors such as hydrophobicity, chemical 
environment, particles size, crystallinity, blood flow, absorptive surface area, and 
resident time at absorptive surface [2]. 
Drug distribution largely depends on blood flow, capillary permeability such as 
in BBB, ligand binding and hydrophobicity. 
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Drug metabolism and elimination primarily depend on afore mentioned 
properties. The drug delivery system can greatly impact each pathway, and, therefore, 
the delivery system is a critical design component in pharmaceutical sciences. 
Lipophiles (or) poorly water soluble drug, perform pivotal rotes in numerous 
biological processes. Many leadingsmall molecules drug are lipophilic. Anticancer drug 
including piposulfan, etoposide, camptothecin and paclitaxel are lipophilic. Antifungal 
drugs such as amphotericin-B, fluconazolo, itraconazoie are lipophilic. Key antioxidants 
such as vitamin A, vitamin E, retinol, lycophene and β-carotene also are lipophilic. 
These lipophiles must be formulated and delivered in a safe, efficacious, and cost 
effective manner. Lipophile delivery is extremely challenging and has long been a 
source of frustration in the pharmaceutical sciences. So, it has become more and more 
evident that the development of new drug alone is not sufficient to ensure progress in 
drug therapy. 
Main reasons for failure in therapy include [3]: 
• Insufficient drug concentration due to poor absorption, rapid metabolism, and 
elimination. Drug distribution to other tissues combined with high drug toxicity. 
• Poor drug solubility which excludes iv injection of aqueous drug solution. 
• High fluctuation of plasma levels due to unpredictable bioavailability after per 
oral administration, including the influence of food on plasma levels. 
A promising strategy to overcome these problems involves the development of suitable 
drug colloidal carrier system. 
 
NEED OF COLLOIDAL CARRIER SYSTEMS [57] 
Colloidal carriers have attracted the main interest because they are promising 
systems to fulfill the requirements of a poorly aqueous soluble drug. But, in the first 
Chapter 1                                                                                                         Introduction                            
 3
place, nanosized carriers are treated as hopeful means to increase the solubility and 
therefore the bioavailability of poorly water soluble –activity ingredients belonging to 
the classes II and IV in the biopharmaceutical classification system [BCS] [3, 4]. 
The common characteristic of all colloidal carriers is the sub-micron particle size. 
Corresponding to the broad diversity of colloidal carriers, the possible administration 
routes vary 
• Dermal 
• Peroral 
• Parenteral 
• Ocular 
• Pulmonary application 
As upper limit for IV administration to avoid embolism in blood vessels no particles 
above 5µm and only few particles between one to five micrometers are accepted. Solid 
particular systems are limited to either the subcutaneous (or) intramuscular routes of 
administration; intravenous administration may result in vaso occlusion.      
 
Focusing on the biofate of lipid – containing drug carriers after per oral 
administration, short chain and medium chain liquid lipids are known to be easily 
hydrolyzed and to be readily absorbed in the gastrointestinal tract [GIT]. Crystalline 
lipids are poorly attached by lipases and very long chains (From c18 up) in solid state 
are poorly absorbed. Often penetration and uptake of entire colloidal particles in cell 
tissues is not probable to explain the in vivo effects of colloidal surface area of 
nanoparticles compared to micro particles, Eg: improved drug solubility and 
therefore better bioavailability is given [5]. 
Nanosizing of the bulk material may also lead to dramatic changes of the 
physical properties of the substance,(ie)  the depression of the melting point 
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which results in the existence of super cooled melts. Therefore colloids are not 
trivial system. furthermore, different colloidal structures might co-exit.  
Of course, nanometric systems have to fulfill the request’s for save drug delivery 
systems mentioned above. Most of all, precautions against aggregation, 
coalescence. Additionally incorporation of sensitive drug molecule in some 
carrier matrices is claimed as protection against enzymatic degradation, 
hydrolysis (or0 light. Despite of their small size, colloidal carriers have to 
controlled drug release. 
 
COLLOIDAL DRUG CARRIER SYSTEMS  
A. NANOCAPSULES [6, 7] 
Oil containing nanocapsules differ from nanoemulsions in providing a barrier 
made from polymer between the core and the surrounding environment, but as well 
nanoparticles with aqueous cores in an aqueous outer phase are published. Often, for the 
preparation of nanocapsules the way of solvent displacement and interfacial 
polymerization are applied. 
 According to the liphophilicity of the capsule content, hydrophilicity and 
lipophilic drugs can be dissolved additionally, the polymeric particle surface may serve 
as compartment lipophilic drugs have already shown to be released in t\a controlled 
manner. Encapsulation may decrease the toxicity of drugs after peroral (or) parenteral 
application in as much as the exhibition to cells is diminished. Encapsulation saves 
sensitive drugs from rapid degradation with the aim to reduce the interactions with 
reticuloendothetial system (RES) and to alter body distribution; the surface of 
nanocapsules was modified by certain materials such as surfactants. 
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B. NANOSUSPENSIONS [8, 9]   
Nanosuspensions are saturated solutions. They represent the simplest colloidal 
carriers with respect to composition. The drug payload amounts to nearly 100%. In an 
aqueous environment, the drug is pearl milled, precipitated (or) high pressure 
homogenized to a particle distribution mostly below one micrometer. Despite of the use 
of tensides , particle growth up to micrometric drug crystals may occur when the drug 
molecules of small particles dissolve in the outer environment and precipitate later on 
the surface of larger particles. 
 Due to tremendous interface area between drug and environment, solubilization 
velocity of the drug is increased according to the rays Whitney equation. Attention has 
to be paid on drugs with small safety margins where burst release has to be avoided. But 
controlled reease and reproducible blood levels are not easily achievable because as a 
release controlling barrier only the tenside layer may serve in these nanosuspensions. 
Suspensions of crystals in the µm range are already established in the martiet (eg: 
predigaleu TM). The only two registered nanosuspensions are repamune TM and emend 
TM for immediate delivery. 
 
C. LIPOSOMES [10, 11] 
Liposomes consists of one (or) more lipid bilayers of amphiphilic lipids(ie; 
Phospholipids, cholesterol, glycolipids). The lipophilic moiety of the bilayer is turned 
towards each other and creates an inner hydrophobic environment in the membrane. 
Lipophilic (or) amphiphilic drugs can be associated with non polar parts of lipid bilayers 
if they fit in size and geometry.the hydrophilic molecular head groups face the outer 
water phase and the inner aqueous core of the vesicles. Water soluble compounds can be 
included within the aqueous compartments. 
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Liposomes are classified as large multilamellar liposomes (MLV), large 
unilameller vesicles(LUV), small unilameller vesicles (SUV), oligolameller vesicles 
(OLV) and multivesicular (MVU), depending on the their size, the number of bilayers 
and the existence of inner vesicles in a vesicle. The size of liposomes varies from 20nm 
to few micrometers with lipid membranes approximately 5nm. 
Some of the marketed products are 
• Ambisome TM -parenteral  
• Daunoxome TM-parenteral 
• Prvaryl TM- Lipogel- Topical administration. 
 
D. MIXED MICELLES [10, 12] 
As long – chain phospholipids are known to form bilayers when dispersed in 
water, the preferred phase of short-chain analogues is the micellar phase. In general 
ampholytic molecules, which are able to decrease the surface tension of a solvent, 
arrange in micelles, as Tween TM (or) sodium dodecyl sulfate above a certain critical 
concentration. A micellar solution is a thermodynamically stable system formed 
spontaneously in water and also in organic solvents. The latter is of less interest in 
pharmaceutical technology solute concentration, the critical micellar concentration 
(CMC) and at solution temperatures above the critical micellar temperature (CMT). The 
small colloidal aggregates (micelles) are in rapid thermodynamic equilibrium with a 
measurable concentration of monomers micellar solutions. Exhibit solubilization 
phenomena. The micelle solubilizes last molecules (ie. Drugs) in any zone of the 
micelle volume, but the penetration into the micelle depends over all on the inner space 
of the micelle, on the hydrophobicity of the drug and on the charge of the incorporated 
molecule. The interaction between micelles and lipophilic drugs leads to the formation 
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of mixed micelles (MM), often called as swollen micelles, too the addition of salt, 
alcohol, etc can vary the degree of penetration into the micelle ( Co- solubilization). In 
mixed micelles, the mobility of the micellar phase was found to be decreased due to 
incorporate molecules. Considerably swollen micelles are larger than the analogous 
“free micelles” because solubilization may result mostly from the increase in micellar 
site.  
 
E. COLLOIDAL LIQUID CRYSTALLINE STRUCTURES [13] 
Liquid crystalline phases share features from both liquids and crystalline 
substances. Due to their intermediate state they are named as “meso phase”, too on one 
hand, referring to crystal related phenomena they can be characterized by diffraction 
scanning calorimetry (DSC), X-ray diffraction and polarization microscopy. On the 
other hand, liquid crystals match partially self-organized melts in providing remarkable 
viscosity and diffusion characteristics. 
 
DISADVANTAGE [13] 
The tenside concentrations are high and that colloidal dispersion of liquid 
crystals occur only in a thin range of parameters. Mesophases are thermodynamically 
stable and self-assembling, but they form reversible the former based micellar (or) 
molecular dispersed state by adding water. 
 
F. MICROEMULSIONS [14] 
Microemulsions are optically isotropic, transparent (or) translucent, low-viscous, 
single phasic and thermodynamically stable liquid solution. Microemulsions are 
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bicontinuous systems that are essentially composed of water and oil, separated by 
surfactant and co-surfactant. 
Due to their large interfacial areas microemulsions typically show. Much greater 
solubilizing capacities for both hydrophilic and lipophilic drugs than micellar solution. 
Microemulsions are limited to dermal and per oral administration because of their high 
surfactant concentration. They exist in narrow regions of phase diagrams; therefore they 
are very restricted in tolevance to quantitative formulation change. 
 
DISADVANTAGE [14] 
Microemulsions are unable to dilute and therefore size determination sometimes 
is difficult. 
 
G. NANOEMULSIONS [9] 
Nanoemulsions are heterogenous systems comprised if two immiscible liquid is 
dispersed as droplets in another liquid. O/W nanoemulsions present the most important 
parenteral drug carrier systems where lipophilic drug are dissolved in the inner phase of 
the emulsion. Degradation of the droplets containing lipophilic drug occurs very fast 
when administered intravenously, so retarded release is not realized. With regard to the 
mobility of the oil a protection of sensitive drug molecules from hydrolysis is hindered. 
Moreover sustained release and incorporation of hydrophilic components in 
conventional oil in water is not realizable. Multiple emulisions (w/o/w) are proposed to 
resolve these problems. 
 
DISADVANTAGES [9] 
1) Rapid degradation for oil droplets takes place in GIT if given per orally. 
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2) Unstable systems 
3) Difficult to handle     
 
H. POLYMER NANOPARTICLES [15] 
Polymers suitable for the preparation of nanoparticles include cellulose 
derivatives, poly (alkyl cyanoacrylates) poly (methylidene malonate), polyorthoesters, 
polyanhydrides and polyesters such as poly (lactic acid), poly (glycolic acid) and poly 
(t-caprolactone) and their copolymers. Polymers used for parenteral delivery have to be 
biodegradable; they mostly belong to polyesters (or) to the group of polyacrylates. For 
Peroral administration, non-degradable polymers such as acrylate-and cellulose-
derivatives can be used for nanoparticles designed not be absorbed. 
For the production of polymer nanoparticles various procedures are applied: 
- Coacervation technique 
- Solvent evaporation 
- Solvent diffusion 
- Interfacial polymerization  
- Denaturation of nature proteins 
- Degradation by high shear forces 
- Microfludization 
Depending on the polymer, drug and polymer interaction production procedure, 
drug release differs. 
 
I. SOLID LIPID NANOPARTICLES AND NANOSTRUCTURED LIPID 
CARRIERS [16, 17] 
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Melt- emulsified nanoparticles based on lipids (or) waxes solid at room 
temperature have been developed. 
 
ADVANTAGES [16] 
- Use of physiological well tolerated lipids 
- Avoidance of organic solvents 
- Wide potential application spectrum. 
- avoid toxicity 
- Improved bioavailability 
- Protection of drug molecules  
- Controlled release characteristics 
 
DISADVANTAGES [16] 
- Particle growth 
- Particle aggregation  
- Unpredictable gelation tendency  
- Unexpected dynamics of polymorphic transitions  
- Burst drug release  
- Inherently low incorporation capacities due to the crystalline structure of lipid. 
 
NANOSTRUCTRED LIPID CARRIERS (NLC) [17] 
Also known as oil loaded solid lipid nanoparticles. Liquid lipid solubilizes drug 
much to a higher extent than solid lipids. 
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ADVANTAGES [17] 
- High incorporation capacity (due to the liquid lipid)  
- Control of drug release (due to the encapsulating solid lipid) 
 
 
Figure - 1 
Different Types of Nanocarriers 
 
(a) Nanotubes: self-assembling lipid tubes. (b) Liposomes: concentric bilayered vesicles 
in which an aqueous volume is entirely enclosed by a membranous lipid bilayer. (c) 
Solid lipid nanoparticles (SLN): submicron colloidal carriers made from solid lipids. (d) 
Polymeric nanoparticles. (i) Nanospheres: nanoparticles in which drug is dispersed 
through out the polymeric matrix. (ii) Nanocapsules: nanoparticles in which drug is 
encapsulated within polymeric membrane. (e) Polymeric micelles: amphiphilic block 
copolymers that self-associate in aqueous solution. (f) Dendrimers: macromolecular 
compounds that consist of a series of branches around an inner core. (g) Functionalized 
nanoparticles: monodisperse-sized particles of uniform shape with well-defined surface 
composition. 
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 CHAPTER-II 
SOLID LIPID NANOPARTICLES (SLN) 
Solid lipid nanoparticles typically are spherical with average diameter between 1 
to 1000nm [16, 18]. Solid lipid nanoparticles (SLN) introduced in 1991 represent an 
alternative carrier system to tradition colloidal carriers such as –emulsions, liposomes 
and polymeric micro-and nanoparticles. They are a new generation of submicron-sized 
lipid emulsions where the liquid lipid (oil) has been substituted by a solid lipid.  
 
Figure – 2 
Schematic representation of a Solid lipid nanoparticle [55] 
SLN offer unique properties, such as small size, large surface area, high drug 
loading and the interaction of phases at the interface and are attractive for their potential 
to improved performance of pharmaceuticals. In 1980, speiser and coworkers were the 
first to report making solid lipid particles for drug delivery applications. The reasons for 
the increasing in lipid based system are many-fold and include [16, 17, 19] 
 
 
 
Chapter II                                                                         Solid Lipid Nanoparticles (SLN) 
 13
1) Lipids enhance oral bioavailability and reduce plasma profile variability. 
2) Better characterization of lipoid excipients. 
3) An improved ability to address the key issues of technology transfer and 
manufacture scale-up. 
 
SOLID LIPID NANOPARTICLES (SLN) INGREDIENTS [20] 
General ingredients include solid lipid(S), emulsifier(S) and water. The term 
lipid is used generally in a very broad sense and includes triglycerides (eg. Tristearin, 
hard fat), partial glycerides (eg. Imwitor), pegylated lipid, fatty acid (stearic acid), 
steroids (e.g. cholesterol) and waxes (eg. Cetyl palmitate). Surfactants investigated 
include biological membrane lipids such as lecithin, bile salts such as sodium 
taurocholate, biocompatible non ionics such as ethylene oxide / propylene oxide 
copolymers, sorbitan esters, fatty acid and ethoxylates and mixtures there of. All classes 
of emulsifiers have been used to stabilize the lipid dispersion. The most frequently used 
compounds include different kinds of poloxamer, polysorbates, lecithin and bile acids. It 
has been found that the combination of emulsifiers might prevent particle agglomeration 
more efficiently. 
 
LIPIDS SURFACTANTS 
         TRIACYLGLYCEROLS 
           Tricaprin 
           Trilaurin 
           Trimyristin 
           Tripalmitin 
           Tristearin 
             PHOSPHOLIPIDS 
                    Soy lecithin 
                    Egg lecithin 
               Phosphotidylcholine 
ETHYLENE OXIDE / PROPYLENE 
COPOLYMERS 
                Poloxamer 188 
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ACYL GLYCEROLS 
Glyceryl monostearate 
Glyceryl behanate 
Glyceryl palmitostearate 
      FATTY ACIDS 
          Stearic acid 
          Palmitic acid 
          Deconoic acid 
          Behanic acid 
            WAXES 
      Cetyl palmitate 
CYCLIC COMPLEXES 
         Cyclodextrin 
         Para – acyl – calyx - arenes 
 
           
 
                Poloxamer 182 
                Poloxamer 407 
                Poloxamer 908  
SORBITAN ETHYLENE OXIDE / 
PROPYLENE OXIDE  
COPOLYMERS 
 
                  Polysorbate 20 
                  Polysorbate 80 
                  Polysorbate 60  
ALKYL ARYL POLYETHER 
ALCOHOL POLYMERS 
 
                  Tylopaxal    
BILE SALTS 
                 Sodium cholate 
               Sodium glycolate 
             Sodium tauracholate  
        Sodium taurodeoxy cholate 
ALCOHOLS 
Ethanol 
Butanol 
 
Lipids and surfactants used in the solid lipid nanoparticle production 
Methods of SLN preparation 
1. High shear homogenization [21, 22] 
  High shear homogenization technique was initially used for the production of 
solid lipid nanodispersion. 
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a) Hot homogenization [21] 
 Hot homogenization is carried out at temperatures above the melting point of the 
lipid and is similar to the homogenization of an emulsion. A pre emulsion of the drug 
loaded lipid melt and the aqueous emulsifier phase is obtained by high shearing mixing 
device. The quality of the pre emulsion affects the final product. High pressure 
homogenization of the pre emulsion done above the lipid melting point. Usually lower 
particle sizes are obtained at high viscosity of the liquid phase. Increasing the 
homogenization leads to an increase of the particle size due to particle coalescence, this 
occurs because of kinetic energy of the particles. 
 
Figure - 3 
Partitioning effects on drug during the production of SLN by the hot homogenization 
technique. Left: Partitioning of drug from the lipid phase to the 
Water phase at increased temperature. Right: Re-partitioning of the drug to the lipid 
phase during cooling of the produced O/W nanoemulsion. 
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b) Cold homogenization [22] 
 The cold homogenization process is carried out with the solid lipid and there 
fore is similar to milling of a suspension at elevated pressure. Cold homogenization has 
been developed to overcome the followed problems of the hot homogenization 
technique such as: temperature mediated accelerated degradation of the drug pay load, 
partitioning and hence loss of drug into aqueous phase during homogenization, 
uncertain polymorphic transitions of the due to complexity of the crystallization step of 
the nanoemulsion leading to several modifications (or) super cooled melts. 
Figure - 4 
Comparison of hot and cold high pressure homogenization processes 
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2. Ultrasonication (or) high speed homogenization [23] 
 SLN were also developed by high speed stirring (or) sonication, a most 
advantages are that, equipments that are used here are easily available in every lab. The 
problem of this method is broader particle size distribution ranging in micrometer range. 
This lead physical instability likes particle growth upon storage. Potential metal 
contamination due to ultrasonication is a big problem in this method. So for making a 
suitable formulation studies have been performed at high temperature. 
 
3. SLN prepared by solvent evaporation / emulsification [24] 
 For the production of the nanoparticle dispersions by precipitation of o/w 
emulsions, the lipophilic material is dissolved in which water – immiscible organic 
solvents (cyclohexane) that is emulsified in an aqueous phase. Upon evaporation of the 
solvent nanoparticle dispersion is formed by precipitation of the lipid in the aqueous 
medium. The mean diameter of the obtained particles was 25nm with cholesterol acetate 
as model drug. 
 
4. Microemulsion based SLN preparation [25, 26] 
 Gasco and co workers developed SLN preparation techniques which are based 
on the dilution of the microemulsions. They are made by stirring an optically transparent 
mixture at 65 - 70°C which is typically composed of a low melting point fatty acid 
(stearic acid), an emulsifier (tween 20) and co emulsifier and water. The hot 
microemulsion is dispersed in cold water (2-3°C) under stirring. Typical volume ratios 
of the microemulsion to cold water are in the range 1:25 and 1:50. The dilution process 
is critically determined by the composition of the microemulsion. 
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5. SLN preparation by super critical fluid 
 This is relatively new technique for SLN production and has the advantage of 
solvent – less processing. There are several variations in this platform technology for 
powder and nanoparticle preparation. SLN can be prepared by the rapid expansion of 
super critical carbon dioxide (RESS) method. 
 
6. Spray drying method [16] 
 It is an alternative procedure for lyophilization in order to transform an aqueous 
SLN dispersion into a product. It’s a cheaper method than lyophilization. This method 
particle aggregation due to high temperature, shear forces and partial melting of the 
particle. Frietus and mullera recommends the use of lipid with melting point > 70°C for 
spray drying. The best result was obtained with SLN concentration of 1% in a solution 
of trehalose in water or 20% trehalose in ethanol – water mixtures. 
 
7. Double emulsion method 
 For the preparation hydrophilic loaded SLN, a novel method based on solvent – 
evaporation has been used. Here the drug is encapsulated with a stabilizer to prevent 
drug partitioning to external water phase of w/o/w double emulsion. 
 No single synthesis technique has demonstrated exceedingly superior 
performance. Each technique possesses strengths and weaknesses.  
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TECHNIQUES STRENGTHS WEAKNESSES 
High shear 
homogenization 
 
Ultrasonication 
 
 
High pressure 
homogenization 
 
 
 
Solvent evaporation 
 
 
 
Microemulsion 
 
Low capital cost 
Demonstrated at lab. Scale 
Reduced shear stress 
 
 
Scalable 
Mature technology 
Continous operation 
Commercially 
demonstrated 
No dilution solidification 
Monodisperse distribution 
Low mechanical energy 
input 
Energy intensive process 
Biomolecule damage 
Polydisperse distribution 
Potential metal 
contamination 
Energy intensive process 
Unproven scalability 
Extremely energy 
intensive process 
Polydisperse distribution 
Biomolecule damage 
Residual organic solvent 
Extremely sensitive 
change 
 
Labor  intensive 
formulation work 
                                   
Strengths and weaknesses of different formulation techniques 
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Drug incorporation models of SLN [17] 
• Solid solution model 
• Core shell model 
 
Solid solution model 
 The drug is molecularly dispersed in the lipid matrix when the particles are 
produced by the cold homogenization technique and using no surfactant (or) no – drug 
solubilizing surfactant. 
 
 Core shell model 
 A solid lipid core forms when the recrystallization temperature of the lipid 
surrounding the drug as the membrane. 
 
 
Figure – 5 
 
Proposed structural models for drug loading profiles in lipid nanoparticles 
 
Estimation of incorporated drug 
Entrapment efficiency [16, 17, 27, 28] 
 Is the prime importance in SLN, since it influences the release characteristics. 
The amount of drug encapsulated per unit weight of nanoparticles is determined after 
separation of the free drug and solid lipids from the from the aqueous medium. This 
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separation can be carried out using ultracentrifugation, centrifugation filtration (or) gel 
permeation chromatography.  
 
Centrifugation filtration [26] 
 Filters such as ultra free – MC (or) ultrasort – 10 are used along with classical 
centrifugation techniques. The degree of encapsulation can be assessed indirectly by 
determining the amount of drug remaining in supernatant after centrifugation filtration / 
ultracentrifugation of SLN suspension (or) alternatively by dissolution of the solvent 
and subsequent analysis. 
 
Gel permeation chromatography [32, 33] 
 The unentrapped drug is removed by gel filtration of SLN dispersion through a 
sephadex G – 50 column and elution with phosphate buffered saline (or) normal saline. 
 
Analytical characterization of SLN quality 
 An adequate characterization of the SLN’s necessity for the control of the 
quality of the product. 
 
a) Entrapment efficiency [27, 28, 29] 
 SLN dispersion is prepared, and it is determined for the entrapped drug by 
centrifugation filtration method. SLN dispersion is centrifuged in a refrigerated 
centrifuge and the supernatant is collected and filtered before analyzing the resultant 
solution by appropriate assay method for the drug. 
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                       Wt. of drug incorporated   
Entrapment efficiency = × 100. 
                                             Wt. of drug initially taken 
 
 
b) Particle size and zeta potential [30, 31] 
 Photon correlation spectroscopy (PCS) and laser diffraction (LD) are the most 
powerful techniques for routine measurements of particle size. This method covers a 
range to about 3 microns. PCS is a good tool to characterization of nanoparticles, but it 
is not able to detect larger microparticles. Electro microscopy provides, in contrast to 
PCS and LD, direct information on the particle shape. 
 Zeta potential (ZP) measurements allow predictions about the storage stability of 
colloidal dispersion. 
 
c) Differential scanning calorimetry (DSC) [31] 
 DSC is the most commonly applied to assess the status of the lipid. DSC uses the 
fact that different lipid modifications possess different melting points and melting 
enthalpies. 
 
In vitro drug release from SLN [23, 29, 58] 
 There are various methods used to study the in vitro release of the drug are: 
• Side by side diffusion cells with artificial (or) biological membrane. 
• Dialysis bag diffusion technique 
• Reverse dialysis bag technique 
• Agitation followed by ultracentrifugation (or) centrifugal ultra filtration 
Dialysis tubing is the most commonly used method. 
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Dialysis tubing [29] 
 In vitro drug release could be achieved by using dialysis tubing. The SLN 
dispersion is placed in pre washed dialysis tubing which can be hermetically sealed. The 
dialysis sac then dialyzed against a suitable dissolution medium at suitable intervals. 
 
Influence of ingredient composition on product quality 
Influence of lipid [17, 27, 34] 
 Using the hot homogenization, it has been found that the average particle size of 
SLN increasing with higher melting lipids. SLNs have slower degradation because of 
their solid matrix. The influence of lipid composition of the particle size was also 
confirmed on SLN produced by high shear homogenization. Factors such as velocity of 
lipid crystallization, lipid hydrophobicity, influence of self emulsifying properties of 
lipid on the shape crystals.  
 
Effect of emulsifier [34] 
 Emulsifiers have the impact on the quality of the SLN dispersion. SLN produced 
with lower concentration of the emulsifier leads to microparticles. High concentration of 
the emulsifier reduces the surface tension and facilitates the particle partition during 
homogenization. It could be shown that the degradation velocity increased with 
decreasing length of the fatty acid length when using glycerides as lipid matrix.  
 
 Fate of SLN after oral administration [35, 36, 37] 
 The oral route continues to be a challenge as well as the most attractive way to 
administer drugs because of its unquestionable commercial potential. Incorporation of 
drugs into lipid nanoparticles opens the perspective of enhanced and / or less variable 
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bioavailability and prolonged plasma levels. While these systems may provide the 
greatest flexibility in the modulation of the drug release profile GIT, they may also 
provide protection against chemical degradation for labile drug molecules. 
 
Figure – 6 
 
A diagrammatic representation  of some of the areas where flow and transport of 
nanoparticles is key. I: flow in the GI tract after oral administration; II: access to and 
adhesion to M-cells of Peyer 's patches or to enterocytes; III: passage into the mesenteric 
lymph; IV: flow in the lymph vessels and entrapment in the lymph nodes (not shown); 
V: transport between lymph and blood. A: blood flow; B: adhesion to capillary walls; C: 
extravasation and flow in tissue; D: flow and deposition at vessel bifurcations; and E: 
movement into tumours. Each route (the subcutaneous route is also indicated) will 
involve a complex sequence of nanoparticle pathways, most involving lymph, blood and 
intestinal fluid. 
 
 
Routes of administration and their biodistribution 
 Various administration routes are:  
Per oral administration [38, 39] 
 Yang et al, investigated camptothecin (CA) [39] containing SLN were produced 
from stearic acid 2%, lecithin 1.5%, and poloxamer 188 0.5% claimed encapsulation 
efficiency of CA was 99.6%. the conclusion from the study was that SLN are promising 
sustained release system of CA and other lipiphilic drugs after oral administration. 
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Parenteral administration [39] 
 Yang et al, reported on the pharmacokinetics and body distribution of 
canptothecin after IV injection in mice. Gasco et al, produced stealth and non stealth 
SLN and studied them in cultures of macrophages, and after loading them paclitaxel in 
vivo. 
 
Transdermal application [40] 
 Liu et al, investigated triamcinolone acetonide acetate (TAA) containing SLN 
were produced from compritol 888 ATO (3.6%), soy lecithin (1.8%), Tween 80 (3.0%) 
and claimed encapsulation efficiency was 91.2%. 
 
Cosmetic application [41, 42] 
 Li et al, studied penciclovir [44] loaded SLN composed of glyceryl 
monostearate, tween 80, poloxamer 188, brij 78 for percutaneous permeation and skin 
targeting. 
 Methotrexate [44] loaded SLN composed of cetyl alcohol, stearic acid, tween 80 
was developed as topical gel to improve therapeutic index of methotrexate compared to 
topical formulations currently available in the treatment of psoriasis. 
 
Sterilization of SLN [18] 
 For intravenous and ocular administration SLN must be sterile. The temperature 
reach during sterilization by autoclaving presumably causes a hot o/w micro emulsion 
and probably alters the size of the hot nanoparticles. Autoclaving at 121°C cannot be 
performed when using sterically stabilizing polymers, e.g. poloxamer series. This can be 
avoided by reducing the autoclaving temperature (e.g. 121°C to 110°C, but 
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simultaneously prolonging the autoclaving time). It can be concluded that SLN 
dispersions can also be sterilized by filtration similar to emulsions for parenteral 
nutrition. It is highly important to filter them in the liquid state; this allows even 
particles with a size larger than the pores in the filter to be filtered. 
 
Advantages of SLNs [18, 20, 36] 
 
• Control and / or target drug release  
• Excellent biocompatibility 
• Improve stability of pharmaceuticals 
• High and enhanced drug content 
• Easy to scale up and sterilize 
 
 Disadvantages of SLNs [17, 36] 
• Particle growth 
• Unpredictable gelation tendency 
• Unexpected dynamics of polymorphic transitions 
 
Application of SLN 
SLN as gene vector carrier [30, 45, 46] 
 In one work the gene transfer was optimized by incorporation of the diametric 
HIV – 1 HAT peptide into SLN vector. Ther are several recent reports of SLN carrying / 
genetic / peptide materials such as DNA and peptide materials. 
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SLN as topical use [41, 42]  
 SLN and NLC have been used to for topical application for various drugs such 
as tropilide, imidazole, antifungals, vitamin – A, isotretinoin, ketaconazole, DNA, 
flurbiprofen and glucocorticoids. By using glyceryl behanate as lipid matrix vitamin – A 
loaded SLN was prepared. 
 
SLN as cosmeceuticals [47] 
 The SLN have been applied in the application of sunscreens and as an active 
carrier agent for molecular sunscreens and UV blockers. 
 
SLN for potential agriculture applications [48] 
 Essential oil extracted from Artemesia arboreseens L when incorporated into 
SLN, were able to reduce the rapid evaporation compared with emulsions and the 
systems have been used in agriculture as suitable carrier of safe pesticides. 
 
SLN as targeted as carrier for anticancer drug to solid tumor [38, 44, 49] 
 SLN have been used as drug carriers. Tamoxifen, an anticancer drug 
incorporated in SLN to prolong the release of drug after IV administration in breast 
cancer. Tumor targeting has been achieved with SLN loaded drugs like methotrexate 
and camptothecin.  
 
SLN in breast cancer and lymphnode and metastases [50] 
 Mitoxantrone SLN local injections were formulated to reduce the toxicity and 
improve the safety and bioavailability of the drug. 
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CHAPTER III 
LITERATURE REVIEW 
 
1. Chattopadhyay et a1., developed a lipid nanoparticle system for the  enhanced 
brain delivery of the potent and frequently used HNP1, atazanavir.     
The lipid nanoparticle was prepared by thin film hydration technique. The SLNs were 
analyzed particle size, encapsulation efficiency, morphology, zeta potential and drug 
release. Cell viability experiments demonstrated that SLNs exhibit no toxicity in 
HCMEC/D3 cell. Further more a release of rhodamine -123 by SLNs also resulted in a 
higher cell accumulation. 
 
2. Triplett II M.D et a1., studied about SLN of β-carotene using statistical  
experimental design. Different formulation and high shear homogenization  process  
effects  on  particle  size, stability, drug  release  have  been  investigated .  β-carotene 
was incorporated into stearic acid to investigate the effects of  introducing a drug into 
the base SLN system. β-carotene entrapment efficiency  average 40%. The statistical 
experimental design was found to be much broader that suggested in literature. 
 
3.  Liu. W. et a1., investigated SLN hydrogel for transdermal iontophoretic  drug 
delivery. Triamcinolone acetonide was employed as model drug. SLN containing the 
drug was incorporated into carbopol and gel was prepared. The use of TAA-SLN 
carbopol gel as a vehicle for the transdermal iontophoretic drug delivery of TAA was 
evaluated in vitro using horizontal diffusion cell fitted with porcine ear skin. 
Transdermal penetration of TAA from TAA-SLN carbopol gel cross the skin tissue was 
significantly enhanced by iontophoresis. 
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4. Ugazio.E. et a1., prepared cyclosporine-A (CYA) solid lipid nanoparticles  a  
potent immunosuppressive drug from o/w  microemulsion  method consisting of  stearic 
acid,  phosphotidylcholine and taurocholate. The claimed encapsulation efficiency was 
13%.The SLN was characterized by entrapment efficiency, particle size, morphology 
and in vitro drug release. In vitro release of CYA form SLN is very controlled and it is 
proposed for most administration routes, in particular for the duodenal route. 
 
5.  Abdelbary G. et a1., studied the feasibility of the inclusion of a water  insoluble 
drug diazepam (DZ) into solid lipid nanoparticles(SLN).This work also  describes a new 
approach to prepare suppositories containing DZ-loaded SLN  dispersions, as potential 
drug carrier for the rectal route. Modified high-shear homogenization and ultrasound 
techniques were employed to prepare SLN. The DZ loaded SLN was evaluated for 
entrapment efficiency, particle size, morphology and in vitro drug release. The results 
revealed that the SLN-based suppositories as final dosage form would provide means by 
which the DZ-loaded SLNs would be administered rectally. It appears that SLN and the 
prepared suppositories from SLN offer a promising delivery system for the prolongation 
of DZ release through the rectal route.  
 
6. Xu.Z. et a1., designed and prepared a new docetaxel-loaded hepatoma targeted 
solid lipid nanoparticle (tSLNs) with galactosylated dioleoylphosphotidyl ethanol 
amine. The tSLNs were investigated for cellular cytotoxicity, cellular uptake, 
subcellular localization, in vivo toxicity, therapeutic effect, biodistribution and 
histology. The results showed that the cytotoxicity of tSLNs against hepato celluar 
carcinoma cell line BEL7402 was superior to taxotere® and non-targeted SLNs 
(nSLNs). The studies on cellular uptake and biodistribution indicated better autitumor 
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efficacy of tSLNs. These results implied that tSLNs could enhance its antitumor activity 
in VNO with low system toxicity.  
 
7. Yu et a1., studied to enhance the liver targeting and reduce the side effects by 
synthesizing N1-stearyl-5-fu and incorporation into solid lipid nanoparticles (SLN). N1-
stearyl-5-fu (5-Fus) was prepared by physical agglomeration method. The mean 
diameter of 5-Fus-SLN was 240.19nm and the drug loading was 20.53%.compared with 
5-Fu injection,the distribution of 5-Fu-SLN in mice showed that 5-Fus-SLN could 
double 5-Fu concentration in mice livers. In conclusion, 5-Fus-SLN has significant liver 
targeting properties. 
 
8. Venkateswarlu et a1., studied the enhancement of bioavailability of lovastatin 
by preparing solid lipid nanoparticles (SLN) of lovastatin using triglycerides by hot 
homogenization followed by ultrasanication. Bioavailabilities studies showed that the 
relative bioavailabilitied of lovastatin and lovastatin hydroxy acid of SLN were 
increased by ~173% and ~324% sespectively compared with lovastatin suspension, after 
intraduodenal administration to male wistar rats. 
 
9. Lu et a1., prepared solid lipid nanoparticles of mitoxantrone for local injection 
against breast cancer and its lymph mode matastasas. Film dispersion-vitrasonication 
method was used to prepare mitoxantrone(MTO)-SLN. The claimed encapsulation 
efficiency was 87%. The in vitro release study revealed a profile of sustained release of 
MTO from MTO-SLN without burst effect. Human MCF-7 breast cancer in nude mice 
and animal model of P388 lymph node metastases in kunming mice was investigated for 
therapeutic effects. The percent inhibition of MTO-SLN against breast cancer was 81%. 
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10. Asasutjarit et a1., investigated mode equations describing the effect of solid 
lipid nanoparticles (SLN) formulation compositions on their size and zeta potential 
using face- centered central composite design. SLN was prepared using cetylpalmitate at 
varying concentrations of tween 80 and span 85 mixtures, dimethyldioctadecyl 
ammonium bromide (DDAB) and cholesterol. The ability of SLN to form complex with 
PH is-HIV-hugag was evaluated by electrophoretic mobility shift assay. In conclusion, 
the regression analysis showed that the model equations of responses fitted well with 
quadratic equations.  
 
11. Shafiq-un-nabi et a1., prepared nanoemulsion of highly lipophilic (or) poorly 
water soluble drug to enhance the solubility and bioavailability of lipophilic drug. 
Ramipril was used as model drug. 
 
12. Jores et a1., investigated the structure and performance of NLC’s and SLN’s. 
colloidal dispersion were produced by high-pressure homogenization and characterized 
by laser diffraction, photon correlation spectroscopy, wide angle x-ray scattering and 
differential scanning calorimetry. Nuclear magnetic resonance spectroscopy and 
electron spin resonance experiments performed to investigate NLC nanoparticles 
showed any advantage with respect to incorporation rate to the drug compared with 
conventional nanoemulsions. 
 
13. Murthy S.R. et a1., studied the effect of lipid matrix on the entrapment of 
olanzapine (OL). OL loaded solid lipid nanoparticles was prepared using lipids like 
glyceryl monostearate (GMS), precirol ATO 5 (PRE), glyceryl tristearate (GTS), and 
witepsol E85(WE85) and poloxamer 407 and hydrogenated soya phosphotidylcholine as 
Chapter III                                                                                               Literature Review 
 32
stabilizers using a holt melt emulsification high pressure homogeniziation technique. 
The highest partition coefficient for OL with melted lipids and PH 7.4 phosphate buffer 
(PH 7.4 PB) was obtained with GTS. The entrapmrnt efficiency was in the following 
order. GTS SLNS> PRE SLNs> WE85 SLNs> GMS SLNs. Relase of OL from the 
SLNs was sustained up to 48 hours in PH 7.4 PB and obeyed higachi’s release kinetics. 
 
14. Hou. D et a1., produced solid lipid nanoparticles (SLNs) using modified high 
shear homogenization and ultrasound techniques. Mifepristone had been used as model 
drug. Entrapment efficiency (EE%)of SLNs was more than 87 present and showed 
relatively long-term physical stability as the leakage was very small after being stored 
up for one month. 
 
15. Kuo Y.C. et a1., fabricated cationic solid lipid nanoparticles (CSLNs) by 
microemulsion method. Polysorbate 80 were used as stabilizers,and the lipid phase 
contained cationic stearylamine (SA) and dioctadecyl ammonium bromide (DODAB) 
and non ionic compritol 888 ATO5 (CA) and cacoa butter (CB). Several factors such as 
entrapment efficiency, releases kinetics and the distribution of saquinavir (SQV) in 
(SLNs) were analyzed. The result indicate that the mixture of SA and DODAB and the 
mixture of CA and CB were beneficial to the entrapment efficiency of SQV.      
 
16. Attama.A.A.et.al., investigated the characterization of silid lipid 
nanodispersions (SLN) prepared with a 1:1 mixture of theobroma oil and goat fat and 
phospholipon 90G (P90G) as a stabilizer heterolipid and using polysorbate 80 as mobile 
surfactant. The SLN were characterized by time resolved particle size analysis, zeta 
potential and osmotic pressure measurements, differential scanning calorimetry and 
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wide angle X- ray diffraction (WAXD). Results indicate lipid mixtures produced SLN 
with lower crystallinity an higher particle sizes compared with SLN prepared with 
theobroma oil alone with or without P90G. 
 
17. Heiati.H.et.a1., prepared solid lipid nanoparticles with trilaurin(TL) and 
dipalmitoylphosphatidyl choline (DPPC) or a mixture of DPPC and 
dimyristoylphosphotidyl glycerol (DMPG) to produce SLNs. The in vitro release of 
AZT-P from different SLNs formulation was studied at 37°c using a bulk equilibrium 
reverse dialysis sac technique. Increased drug release was observed in SLNs formulated 
with phospholipids (PLS) having a transition temperature below 37°c. 
 
18.  Paliwal.R.et a1., prepared methotrexate SLN using stearic acid, glyceryl 
monostearate, tristearin, and compritol 888 ATO by solvent diffusion method to study 
the effect of lipid core material on characteristics of solid lipid nanoparticles designed 
for oral lymphatic delivery. The SLN were characterized for shaped, particle size, zeta 
potential and percentage drug content and its release. The comparative study conducted 
on MTX bearing SLN revealed that the formulation that the formulation based on 
compritol 888 ATO could improve the oral bioavailability of MTX.  
 
19.  Rudolph et a1., studied to optimize gene delivery of SLN-based gene vectors 
by incorporation of a dimeric HIV-1 TAT (peptide) TAT2 into SLN gene vector. In 
vitro studies revealed TAT2 into SLN gene vectors induce an increase of gene 
expression when compared with mutant TAT2-M1 and 4-8 times higher as compared 
with PEI. 
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20.  Bargoni et a1., studies the uptake and transport of solid lipid nanoparticles 
(SLN) into the lymph and blood after duodenal administration in rats. Unlabelled and 
labeled SLN (average diameter of 80nm) were administered intraduodenally to rats. The 
biological sample were analyzed by photon correlation spectroscopy (PCS), 
transmission electron microscopy (TEM). TEM analysis evidenced SLN in lymph and 
blood after duodenal administration to rats. 
 
21. Jani et a1., studied the oral absorption of fluorescent polystyrene nanospheres, 
of diameters ranging from 50nm to 3µm, administered orally to rats for 10days, and 
found that uptake and translocation were inversely size dependent. 
 
22. Huang G.et a1., prepared temozolomide solid lipid nanoparticles (TMZ-SLNs) 
by emulsification and low temperature solidification method. In vitro drug release was 
conducted in phosphate buffered saline (PH 6.8) at 37°c. The results show that the 
TMZ-SLNs had an average diameter of 65.9±36mv and the in vitro drug release was 
monitored for up to 3 days. And the release behavior was in accordance with higuchi 
equation. 
 
23. Reddy et a1., prepared solid lipid nanoparticles of etoposide using glyceryl 
monostearate (monoglyceride), glycerol distearate (diglyceride) and tripalmitin by slight 
modification of melt emulsification and homogenization technique. The melt was that 
heated to 5°c above the melting point of glycerides and emulsified using a blade-type 
stirrer at 2000rpm. 
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24. Fang.Y. et a1., developed solid lipid nanoparticles using precirol ATO 5. SLN 
showed mean particle size of 300nm. Tween 80 and soyabean lecithin and used as 
emulsifiers. Differential scanning calorimetries studied were performed to characterize 
the physiochemical properties of SLN. 
 
25. Helgason.T et a1., studied the effect of surfactant and stability of tween 20 
stabilized tripalmitin solid lipid nanoparticles (SLN). A lipid phase of 10% w/w and 2% 
tween 20 was used. The mean particle diameter of 134nm was observed. At low 
surfactant concentration (<1%w/w) the SLN formed gels, at higher surfactant 
concentration (>1%w/w) a homogenous dispersion was formed. 
 
26. Singh et a1., investigated solid lipid nanoparticles of vitamin-A palmitate using 
high pressure homogenization technique. The nanoparticle dispersion was evaluated for 
various parameters such as particle size, in vitro drug release. The SLN showed a mean 
particle size of 350 nm. DSC studies revealed no drug – excipient incompatibility. In 
vitro drug release studies showed prolonged drug release up to 24 hours.  
 
27. Doijad et al., studied the overall improvement in the efficacy and enhancement 
of therapeutic index. Cisplatin loaded solid lipid nanoparticles (SLN) was prepared 
using microemulsification method by stearic acid, soy lecithin and sodium glycolate. 
The formulations were characterized with respect to size, morphology, zeta potential, 
entrapment efficiency, in vitro drug release profile and stability. SLN were oval with a 
diameter ranging from 250 to 500nm. Entrapment efficiency was found to be 74.53%. 
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28. Lai et a1., investigated cubic nanoparticles of glyceryl monooleate 
(GMO)/poloxamer 407 as potential oval drug delivery system to enhance the 
bioavailability of water insoluble model drug simvastatin. The mean diameter of cubic 
nanoparticles varied within the range of 100-150nm. Entrapment efficiency over 98% 
was achieved due to high affinity of simvastatin to the hydrophobic regions of the cubic 
phase.  
 
29. Bhalekar et a1., prepared miconazole nitrate loaded solid lipid nanoparticles 
(MN-SLN) effective for topical delivery. Compritol 888 ATO as lipid, propylene glycon 
(PG) to increase solubility of the lipid, tween 80 and glyceryl monostearate were used as 
surfactants. SLN exhibited average size between 244 and 799nm. Entrapment efficiency 
ranging from 80% to 100%. The MN-SLN was characterized for particle size and 
entrapment efficiency.  
 
30. Luo.Y. et a1., prepared vinpocetine loaded solid lipid nanoparticles using 
glyceryl monostearate. Ultrasonic solvent emulsification technique was used. SLNs 
were investigated for mean particle size, drug loading capacity, drug entrapment 
efficiency (EE), ε1 zeta potential. The drug release was preformed in 0.1m Hcl, distilled 
water and phosphate buffer saline PH 7.4 using the dialysis bag method. In vitro release 
study showed a prolonged release for up to 96 hours. 
31. Li.H.et a1., designed queretin loaded solid lipid nanoparticles (QT-SLNs) to 
evaluate the potential of using (SLNs) as an oval delivery carrier for poorly soluble 
drug. QT-SLNs were prepared by emulsification ε1 low temperature solidification. The 
average drug entrapment efficiency, drug loading and zeta potential were characterized. 
In vitro drug release studies were performed by using dialysis bag diffusion technique. 
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The SLN dispersion is loaded into pre soaked dialysis bags and placed in conical flask. 
The conical flask was placed at 37°C at a rate of 100 rpm. 
 
32. Subedi.R.K. et a1., prepared solid lipid nanoparticles loaded with doxorubicin 
by solvent emulsification diffusion method using glyceryl caprate as lipid corn. The 
mean particle size measured by photon correlation spectroscopy was 199nm. The 
entrapment efficiency and drug loading capacity were investigated. In vitro release 
studies were preformed by dialysis bag diffusion technique. SLN dispersion was 
transferred to the dialysis tube and then sealed tube was introduced into conical flask 
containing phosphate buffer saline PH 7.4 at 37±1°C and 50 strokes per minute. 
 
33. Jawahar.N. et a1., designed poly (D,L-Lactide-co-glycolide) (PLGA) 
nanoparticles of ramipril by nanoprecipitation method using tribloere polymeric 
stabilizer (pluronic F-68). The particles were characterized for drug content, particle 
size, and particle morphology. In vitro release studies were performed by dialysis bag 
diffusion technique. The prepared nanoparticles were placed in the dialysis bag and 
immersed in 50ml of phosphate buffer saline (PBS) PH 7.4. The entire system was kept 
at 37°± 0.5°C with continuous magnetic stirring at 200 rpm. The amount of drug 
dissolved was determined with uv-spectrophotometry at 207nm. 
 
34. Wang et a1., prepared total flavones of hippophae thamnoides (TFH) solid lipid 
nanoparticles by heating ultrasonic dispersion and lyodhilization. Using monostearin as 
lipid and poloxamer 188 as surfactant. SLN were characterized for mean for mean 
particle size, zeta potential and entrapment efficiency. The percentage of incorporated 
drug in the lipid matrix was determined by ultracentrifugation. In vitro release study was 
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performed within 48 hours after the preparation of SLN. The TFH SLN dispersion held 
a uniform particle size distribution of about 200 nm. TFH SLN has a good sustained 
release effect.                                                     
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CHAPTER-IV 
SCOPE OF WORK 
            Hypertension (or) high blood pressure is a medical condition where in the blood 
pressure is chronically elevated. Persistent hypertension is one of the risk factors for 
strokes, heart failure and arterial aneurysm, and is a leading cause of chronic renal 
failure. 
 Anti hypertensive drugs act by reducing the cardiac output and / or reducing 
the total peripheral resistance, without correcting the cause. Anti hypertensive drugs 
may ultimately reduce BP in humans by more than one mechanism. Further, the 
hemodynamic alterations produced by a single parenteral dose of a given drug may 
differ from the effects resulting from its prolonged oral administration [59]. 
 Ramipril, a potent anti hypertensive drug is almost completely converted to its 
active metabolite ramiprilat (a dicarboxylic acid) by hydrolytic cleavage of the ester 
group in the liver, which has about 6 times the angiotension – converting enzyme 
inhibitor activity of ramipril. Ramipril categorized as a class IV / II drug according to 
biopharmaceutical classification system (BCS) because of its low solubility and poor 
permeability. Ramipril is a highly lipophilic log P (octanol / water) 3.22, poorly water 
soluble drug with absolute bioavailability of 28 – 30% of variable oral absorption. The 
poor oral bioavailability is due to the poor / low solubility and poor permeability [52]. 
 Ramipril undergoes significant ‘first pass metabolism’. The half life of 
ramipril and its metabolite is 2 and 18 hrs respectively. 
Based on these, the aim this current study was to produce and characterize ramipril 
loaded solid lipid nanoparticles using various monoglycerides (Glyceryl monostearate 
and Glyceryl monooleate), non ionic surfactants (Tween 80, Span 20 and Poloxamer 
188) as stabilizers by hot homogenization and ultrasound dispersion method. 
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 Because solid lipid nanoparticles, an alternative colloidal carrier (transport) 
system having ability to improve the solubility / permeability of lipophilic drugs and 
enhance drug absorption and toxicity. SLN improve targeting and stability of drug. 
 Thus the objective of SLN as an alternative colloidal carrier system of ramipril 
was developed for improving the dissolution rate of ramipril that would increase the 
biological activities.            
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PLAN OF WORK 
 
PART-I 
1. Determination of λmax of Ramipril 
2. Calibration curve for the drug in distilled water and phosphate buffer saline 
pH7.4 
 
 
PART-II 
1. Formulation of ramipril loaded solid lipid nanoparticles using different 
concentrations of non ionic surfactants (Tween 80, Poloxamer 188 and Span 20) 
and lipids (Glyceryl monostearate and Glyceryl monooleate) by hot 
homogenization and ultrasound  dispersion method. 
 
PART-III 
Evaluation of Ramipril loaded solid lipid nanoparticles  
1. Determination of entrapment efficiency 
2. In –vitro release characteristics of SLN dispersion in phosphate buffer saline PH 
7.4 
 
 
PART-IV 
1. Measurement of particle size of ramipril loaded solid lipid nanoparticles. 
2. Morphological studies of SLN dispersion using scanning electron microscopy 
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PART-V 
1. Stability studies of SLN dispersion at refrigerated and room temperature. 
 
PART-VI 
1. Differential scanning calorimetry studies of selected formulations to determine 
the status of the drug and lipid.  
2. IR studies to determine interaction between lipids and drug. 
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CHAPTER-V 
MATERIALS AND EQUIPMENTS 
 
 
MATERIALS USED 
 
1. Drug- Ramipril     - Madras Pharma 
 
2. Glyceryl monostearate    - Central drug house 
 
3. Glyceryl monooleate     - Otto chemicals 
 
4. Poloxamer 188      - Madras Pharma 
 
5. Polysorbate 80     - Sisco research lab 
 
6. Sorbiton monolaurate     - Loba chemie 
 
7. Chloroform      - Rankem 
 
8. Methanol      - Rankem 
                                                                                        
9. Sodium chloride     - Central drug house                    
                                                                                       
10.  Potassium dihydrogen ortho phosphate  - Nice chemicals 
 
11. Disodium hydrogen ortho phosphate   - Qualigens 
 
12. Dialysis memebrane 50 – LA 387   - Himedia 
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EQUIPMENTS USED 
 
 
1. Rotary Flash Evaporator   - Super fit rotary flash evaporator  
2. Ultra Sonicator   - Vibronic’s Ultrasonic processor 
3. Mechanical stirrer   -  Scientific industries  
4. Electronic Balance   - A&D Company, Japan 
5. Magnetic Stirrer   - MC Dalal & co  
6. UV Visible Spectrophotometer - UV Pharma Spec 1700, Shimadzu 
7. Refrigerator    - Kelvinator  
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CHAPTER-VI 
DRUG PROFILE 
RAMIPRIL –DRUG PROFILE [51, 52, 53, 54, 60] 
 
Structure                                
 
 
Chemical name 
                  ( 2s, 3as, 6as ) – 1 {(s) – N – [(s) – 1 – carboxy – 3 phenyl propyl] alanyl } 
octahydro cyclopenta (b) pyrrole  - 2 – carboxylic acid, 1 – ethyl ester   
 
Emperical Formula                      : C23H32N2O5 
 
Description   
  Nature   :  white crystalline powder 
  Solubility  :  Freely soluble in methanol, slightly  
      Soluble in water 
  Melting point  :  105°c and 112°c 
                      Molecular weight :  416.511gm/mol 
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Category 
 Angiotensin-converting Enzyme (ACE Inhibitors Systemic) 
 
Identification 
UV light absorption at 207 nm. 
 
Pharmacodynamic  properties 
 Ramipril an angiotensin-converting enzyme inhibitor. Ramipril an inactive 
prodrug is converted to active metabolite ramiprilat in liver. Ramiprilat the active 
metabolite competes with angiotensin converting enzyme blocking the conversion of 
angiotensin I to angiotensin II . It is a vasoconstrictor and a negative feedback mediator 
for renin activity. Lower concentrations result in decrease in blood pressure and an 
increase in plasma renin. Ramiprilat may also act on kininase II, an enzyme identical to 
ACE that degrades vasodilator bradykinin.  
 
Pharmacokinetic properties 
Absorption 
¾ Extent of absorption in gastrointestinal tract is atleast 50 % to 60 %. 
¾ T max is 1 hour for parent compound, 2 to 4 hour for metabolite. 
¾ Plasma half life 2 to 4 hours. 
Metabolism 
¾ Ramipril is converted to active metabolite Ramiprilat in liver by the 
enzyme  
¾ Ramiprilat has 6 times greater ACE inhibition activity than the parent 
compound. 
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Excretion  
¾ 60 % of parent compound and metabolites are excreted in urine. 
¾ 40 % of parent compound and metabolites are excreted in Faeces. 
¾ Less than 2 % of unchanged drug excreted in urine. 
 
Pharmacokinetic characters of Ramipril 
¾ Oral Bioavailability  : 28 %  ( Ramipril )   
      44 % ( Ramiprilat ) 
¾ Urinary excretion  : Renal (60 %), Fecal (40 %). 
 
¾ Plasma protein binding : 73 %  ( Ramipril )   
     56 % ( Ramiprilat ) 
Therapeutic indications 
¾ Hypertension 
¾ Congestive heart failure 
¾ Myocardial Infarction 
¾ To prevent stroke, Cardiovascular death. 
 
Dose 
¾ 5 to 10 mg per day. 
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Adverse Effects 
¾ Postural Hypotension 
¾ Hyperkalemia 
¾ Cough 
¾ Angio edema 
¾ Neutropenia 
¾ Agranulocytosis 
¾ Anaphylactoid reactions 
¾ Nausea 
¾ Vomiting 
¾ Dizziness 
 
Drug Interactions 
¾ Hyperkalemia with potassium sparing diuretics and potassium 
supplements. 
¾ Antacids reduce bioavailability of Ramipril. 
¾ Indomethacin(and other NSAIDS) attenuate the hyoptensive action. 
 
Special Precautions 
¾ Don’t take  potassium supplements without seeking medical advice 
¾ Don’t take during pregnancy. 
 
Contra-indications 
¾ Renovascular disease. 
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¾ Severe renal impairment. 
¾ History of angio edema. 
¾ During Pregnancy. 
¾ Hypotension.   
 
International Brand Names 
Acovil (ES)  
Altace (VE)  
Cardace (ID, IN)  
Corpril (TH)  
Delix (DE)  
Heartprilprotect (KP)  
Hyperil (ID)  
Hypren (AT)  
Lostapres (AR)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter VII                                                                                              Excipients Profile 
 50
CHAPTER-VII 
EXCIPIENTS PROFILE 
    
GLYCERYL MONOSTEARATE [61] 
 
SYNONYM 
 
 Glyceryl stearate,  Monostearin 
 
STRUCTURE 
  
CHEMICAL NAME 
 3-Stearoyloxy-1,2-propanediol; Glyceryl stearate; Alpha-Monostearin; 
Monostearin; Octadecanoic acid, 2,3-dihydroxypropyl ester; Glycerin 1-monostearate; 
Glycerin 1-stearate; Glycerol alpha-monostearate; Glyceryl 1-monostearate; Stearic acid 
alpha-monoglyceride; Stearic acid 1-monoglyceride; 1-Glyceryl stearate; 1-
Monostearin; 1-Monostearoylglycerol; 1,2,3-Propanetriol 1-octadecanoyl ester. 
 
EMPIRICAL FORMULA 
CH3 (CH2)16COOCH2CHOHCH2OH 
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MOLECULAR WEIGHT 
 358.56 
 
FUNCTIONAL CATEGORY 
¾ Emulsifying agent 
 
DESCRIPTION 
 White or cream colored waxy solid. 
 
PROPERTIES 
 Physical state  : white powder 
 Melting point  : 63 - 68 oC  
 Boiling point  : > 100 oC 
 Solubility in water : soluble in hot water 
 Solvent solubility : soluble in methanol and chloroform mixture 
 HLB value  : 5.0 
 
STABILITY AND STORAGE CONDITIONS 
 It is stable under ordinary conditions, and should be stored in a well-closed 
container and protected from light. 
 
SAFETY 
 It is generally regarded as an essentially non-toxic and non-irritant material at 
the levels employed as an excipients. 
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HANDLING PRECAUTIONS 
Keep away from heat. Keep away from sources of ignition. Empty containers pose a fire 
risk, evaporate the residue under a fume hood. Ground all equipment containing 
material. Do not breathe dust. 
 
REGULATORY STATUS 
 Induced in the FDA inactive ingredients. Recognized by GRAS status. 
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GLYCERYL MONOOLEATE [61, 62, 63] 
 
SYNONYM 
 1 - Glyceryl monooleate, monoolein 
 
STRUCTURE 
  
 
CHEMICAL NAME 
 3-Stearoyloxy-1,2-propanediol; Glyceryl stearate; Alpha-Monostearin; 
Monostearin; Octadecanoic acid, 2,3-dihydroxypropyl ester; Glycerin 1-monostearate; 
Glycerin 1-stearate; Glycerol alpha-monostearate; Glyceryl 1-monostearate; Stearic acid 
alpha-monoglyceride; Stearic acid 1-monoglyceride; 1-Glyceryl stearate; 1-
Monostearin; 1-Monostearoylglycerol; 1,2,3-Propanetriol 1-octadecanoyl ester. 
 
EMPIRICAL FORMULA 
CH3 (CH2)16COOCH2CHOHCH2OH 
 
MOLECULAR WEIGHT 
 358.56 
 
FUNCTIONAL CATEGORY 
¾ Emulsifying agent 
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DESCRIPTION 
 White or cream colored waxy solid. 
 
PROPERTIES 
 Physical state  : white powder 
 Melting point  : 63 - 68 oC  
 Boiling point  : > 100 oC 
 Solubility in water : soluble in hot water 
 Solvent solubility : soluble in methanol and chloroform mixture 
 HLB value  : 5.0 
 
STABILITY AND STORAGE CONDITIONS 
 It is stable under ordinary conditions, and should be stored in a well-closed 
container and protected from light. 
 
SAFETY 
 It is generally regarded as an essentially non-toxic and non-irritant material at 
the levels employed as an excipients. 
 
HANDLING PRECAUTIONS 
Keep away from heat. Keep away from sources of ignition. Empty containers 
pose a fire risk, evaporate the residue under a fume hood. Ground all equipment 
containing material. Do not breathe dust. 
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POLOXAMER 188 [61, 64] 
SYNONYM 
 Lutrol F 68, Pluronic F 68 
 
STRUCTURE 
 
 
CHEMICAL NAME 
 
 Polyethylene-Polypropylene Glycol 
  
EMPIRICAL FORMULA 
HO(C2H4O)a(C3H6O)b(C2H4O)aH 
 
MOLECULAR WEIGHT 
 8400.00 
 
FUNCTIONAL CATEGORY 
¾ Emulsifying agent 
¾ Sensitize drug resistant cancers to chemotherapy 
 
DESCRIPTION 
 White to off white granules 
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PROPERTIES 
 Physical state  : white powder 
 Solubility in water : soluble in water 
 Solvent solubility : soluble in methanol and chloroform mixture 
 HLB value  : 29.0 
 
BIOLOGICAL EFFECTS OF POLOXAMER 
 Originally thought to be inert carrier molecules work led by Kabanov has 
recently shown that some of these polymers have a very real effect on biological 
systems independently of the drug they are transporting. The poloxamers have been 
shown to incorporate into cellular membranes affecting the microviscosity of the 
membranes. 
STABILITY AND STORAGE CONDITIONS 
 It is stable under ordinary conditions, and should be stored in a well-closed 
container and protected from light. 
 
SAFETY 
 It is generally regarded as an essentially non-toxic and non-irritant material at 
the levels employed as an excipients. 
 
HANDLING PRECAUTIONS 
Keep away from heat. Keep away from sources of ignition. Empty containers pose a fire 
risk, evaporate the residue under a fume hood. Ground all equipment containing 
material. Do not breathe dust. 
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POLYSORBATE 80[65] 
SYNONYM 
 Atlas E, Cappmul POE-O, Glycospere o-20,Tego SMO 80,Tego SMO 80 X, 
Tween 80. 
 
STRUCTURE 
 
CHEMICAL NAME 
(Z) Sorbitan mono-9- Octadecanoate poly (oxy 1,2, ethanediyl) derivatives. 
 
EMPIRICAL FORMULA 
 C64 H124 O26 
 
MOLECULAR WEIGHT 
 1310.00 
 
DESCRIPTION 
 Yellow oily liquid.  
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METHOD OF MANUFACTURE 
Polysorbates are prepared from sorbitol in a three-step process. Water is initially 
removed from the sorbitol to form a sorbitan (a cyclic sorbital anhydride). The sorbitan 
is then partially esterified with a fattyacid such as oleic acid (or) stearic acid to yield a 
hexiton ester. Finally, ethylene oxide is chemically added in the presence of a catalyst to 
yield the polysorbates  
 
PROPERTIES 
Acid value          – 2.0 
 Hydroxyl value          – 65 – 80 
 Saponification value   – 45 - 55 
 Density (g/cm3)     – 1.08g/cm3 
 HLB Value     – 15 
 Solubility     – Soluble in ethanol and water. Insoluble in                  
                                                 Mineral oil and vegetable oil. 
    
FUNCTIONAL CATEGORY 
¾ Emulsifying agent 
¾ Nonionic surfactant 
¾ Solubilizing agent 
¾ Wetting agent 
¾ Dispersing / Suspending agent. 
 
STABILITY 
¾ Gradual soap formation occurs with strong acids or bases 
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¾ Stable in weak acids or bases. 
 
STORAGE 
 It should be stored in a well-closed container in a cool, dry place. 
 
SAFETY 
¾ Daily intake according to the WHO limit is about 25mg/Kg body weight  
¾ LD50 (Mouse, oral)-25g/Kg. 
 
HANDLING PRECAUTIONS: 
 Eye protection and Gloves are recommended. 
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SORBITAN MONOLAURATE [66, 67] 
SYNONYMS 
 Arlacal 20, Span 20, Sorbitan monolaurate. 
 
STRUCTURE 
 
CHEMICAL NAME 
Sorbitan monododecanoate 
 
 
EMPIRICAL FORMULA 
 C18H34O6 
 
MOLECULAR WEIGHT 
 346.46 
 
DESCRIPTION 
 It occurs as yellow viscous liquid with a distinctive odour and taste. 
 
METHOD OF MANUFACTURE 
 Sorbitol is dehydrated to form a hexitan(1,4 Sorbitan) which is then esterified 
with the desired fatty acid. 
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FUNCTIONAL CATEGORY: 
♦ Emulsifying agent. 
♦ Non ionic Surfactant. 
♦ Solubilizing agent. 
♦ Wetting agent. 
 
PROPERTIES 
Acid value              : 
Hydroxyl value      :  
Iodine value           : 
Density (g/cm3)     :  
HLB Value            : 
Melting point         : 
Solubility               : 
3 to 7 
270 to 303 
≤ 1 
1.032 gm/ml 
8.6 
430C - 48oC 
Soluble in oils and in most organic 
solvents. Insouble but dispersible in 
water. 
STABILITY 
♦ Gradual soap formation occurs with strong acids or bases. 
♦ Stable in weak acids or bases. 
 
STORAGE 
 It should be stored in a well-closed container in a cool, dry place. 
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CHAPTER-VIII 
EXPERIMENTAL PROTOCOL 
STANDARD CURVE FOR RAMIPRIL 
PREPARATION OF CALIBRATION MEDIUM [68]  
Phosphate buffer saline PH 7.4 
Dissolve 1.6 gm of sodium chloride, 0.038 gm of potassium dihydrogen 
phosphate, 0.472 gm of disodium hydrogen phosphate in specified quantity of distilled 
water and this solution is placed in 200ml volumetric flask and make up to the volume 
with distilled water. 
 
PREPERATION OF STANDARD CURVE FOR RAMIPRIL [29] 
The standard stock solution of ramipril is prepared by dissolving a known amount of 
drug in methanol and diluted with distilled water. From the above stock solution, drug 
having different concentration of 5, 10, 15, 20 … 50μg /ml is prepared in distilled water. 
 The resulting solution is scanned in UV spectrophotometer to find the λmax and 
the absorbance is measured at λmax (207nm). Taking concentration in X-axis and 
absorbance in Y-axis plots the standard curve. 
 The standard curve is prepared similarly in phosphate buffer saline PH 
7.4. The standard curve is used to estimate drug content, entrapment efficiency and 
percentage drug release. 
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 FORMULATION OF RAMIPRIL LOADED SOLID LIPID NANOPARTICLES 
[5, 20, 21, 31, 69, 70] 
 Solid lipid nanoparticles are prepared by a hot homogenization followed by 
ultrasonication method. Ramipril loaded solid lipid nanoparticles is prepared by using 
two different type of lipids (monoglycerides) glyceryl monostearate and glyceryl 
monooleate (6% W/V) and various surfactants tween 80, poloxamer 188 and span 20 
(1.0%, 1.5% and 2.0% W/V) are used as stabilizers to enhance the solubility of the drug 
in the lipid.  
The drug concentration is kept as constant for each formulation (1mg/ml).the 
formulations are represented in Table 1. 
 
PREPARATION OF RAMIPRIL LOADED SOLID LOADED 
NANOPARTICLES [20, 21, 31, 69, 70] 
Ramipril loaded SLN is prepared by a hot homogenization followed by 
ultrasonication method. Ramipril (0.16% W/V to the lipid), monoglyceride (6% wt/vol) 
is dissolved in a 10 ml mixture of methanol and chloroform (1:1). Organic solvents are 
completely removed using a rotary flash evaporator. The embedded lipid layer was 
melted by heating 5°C above the melting point of the lipid. An aqueous phase is 
prepared by dissolving Tween 80 or Poloxamer 188 or Span 20 (1.0% or 1.5% or 2.0% 
W/V) in distilled water (sufficient to produce 30 ml of preparation) and heating to the 
same temperature of the oil phase. The hot aqueous phase is added to the oil phase and 
homogenization is performed (at 2500 rpm and 70°C) using a mechanical stirrer for 30 
minutes. The coarse oil in water emulsion so obtained is ultrasonicated using a 
vibronic’s ultrasonic processor for 25 minutes. Ramipril loaded SLN is finally obtained 
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by allowing the hot nanoemulsion to cool to room temperature and stored at 4°C in 
refrigerator.  
 
EVALUATION OF RAMIPRIL LOADED SLN [23, 29, 31, 38, 46, 69, 70, 71, 72, 
73] 
 The formulated ramipril loaded solid lipid nanoparticles are evaluated for its 
entrapment efficiency, drug content and in vitro drug release studies in phosphate buffer 
saline PH 7.4. 
 
Determination of entrapment efficiency [29, 31, 38] 
 Entrapment efficiency of SLN dispersion is determined by centrifugation 
filtration method. SLN dispersion containing 5mg of drug is placed in a refrigerated 
centrifuge and centrifuged at 20000 rpm for 1 hour and the supernatant is collected and 
filtered. The filtered solution is made up to desired volume with fresh phosphate buffer 
saline pH 7.4. The amount of drug that is not incorporated in the SLNs could be 
obtained by the UV – detection absorption percent.  
 The absorbance of the samples is measured at 207nm to estimate the percentage 
entrapment efficiency. 
 The entrapment efficiency is calculated by following formula: 
                   Wt. of drug incorporated   
Entrapment efficiency= × 100. 
                                        Wt. of drug initially taken 
 
In vitro drug release [29, 69, 72]  
 The in vitro release of ramipril from different SLN was determined using 
dialysis bag diffusion technique. An accurately weighed amount of ramipril loaded SLN 
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dispersions equivalent to 2.5 mg ramipril is transferred to dialysis bag and sealed. The 
sealed bag is then suspended in a beaker containing 250ml of phosphate buffer saline 
pH 7.4 and it was allowed to rotate at a constant speed (50 rpm) at 37°C ± 0.5°C. 
Aliquots are withdrawn at predetermined intervals from the receptor compartment up to 
12 hours and the same is replaced with fresh buffer and then the drug content is 
determined spectrophotometrically by measuring the absorbance at 207nm using 
respective receptor medium as blank to calculate the amount of drug released fro 
nanoparticles.     
 
Particle size analysis [23, 46, 73] 
 The mean diameter of SLNs in the dispersion is determined by photon 
correlation spectroscopy (PCS) at a fixed angle of 90° at 25°C. Particle size is 
determined by using blue wave (microtrek) using disposable sizing cuvette. Before 
measurement 1 drop of sample is taken from each selected formulated nanosuspension 
and diluted in 10 ml of the dispersion medium (distilled water).   
 
Scanning electron microscopy [71] 
 Average particle size and surface morphology of SLN are evaluated using 
scanning electron microscopy. A brass specimen stub is used for mounting the sample, 
and the wet sample is dried in room temperature and then coated with gold under 
vacuum for 60 seconds. Then the sample is observed under scanning electron 
microscope. 
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FT - IR studies [29, 70] 
The interaction between the lipids with drug is studied by using IR 
Spectrophotometer. Drug, lipid and selected formulations are subjected to FTIR studies. 
 
Stability studies [31, 38, 74] 
 All formulations of ramipril loaded SLN are subjected to stability studies. 
They are stored in two different temperatures, 40C and 25±20 C and the 
entrapment efficiency is estimated for every 15 days.
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CHAPTER-IX 
RESULTS AND DISCUSSION 
STANDARD CURVE OF RAMIPRIL [29, 68]  
 The λ max of ramipril was determined by scanning the 10μg/ml of the drug 
solution in distilled water and phosphate buffer saline PH 7.4. It showed the λ max of 
207nm in both distilled water and phosphate buffer saline PH 7.4.  
 Linear correlation coefficient was obtained for calibration of ramipril in 
each medium. Ramipril obeys the beer’s law within the concentration range of 5 to 50 
μg/ml. Calibration plots of ramipril in both medium was shown in figure 7, 7a and 8. 
The λ max of ramipril is showed in UV graph. 
 
 FORMULATION OF RAMIPRIL LOADED SOLID LIPID NANOPARTICLES 
 Ramipril loaded solid lipid nanoparticles is prepared by using two different type 
of lipids (monoglycerides) glyceryl monostearate and glyceryl monooleate (6% W/V) 
and various surfactants tween 80, poloxamer 188 and span 20 (1.0%, 1.5% and 2.0% 
W/V) are used as stabilizers to enhance the solubility of the drug in the lipid. The 
prepared SLN dispersion was found to be uniform and homogenous in appearance.  
 
ENTRAPMENT EFFICIENCY 
 In order to attain optimal encapsulation efficiency, several factors were varied 
including the type and concentration of the lipid and surfactant material used. In all the 
formulations, the impact of lipid and surfactant concentration was significant this was 
shown in table no: 4 and Figure 9. 
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Effect of surfactants on entrapment efficiency 
  For all SLN formulations prepared with Poloxamer 188 as stabilizer 
shows higher entrapment efficiency, the increase in the Poloxamer 188 concentration 
increased the entrapment as it was acting as a steric stabilizer (F4, F5, F6, F13, F14, 
F15). While the formulations (F1, F2, F3, F10, F11, F12) containing glyceryl 
monostearate and glyceryl monooleate as lipid material respectively, the increase in the 
entrapment upon increasing  tween 80 concentration could be attributed to the added 
emulsification and stabilization effect of this lipid material in the presence of tween 80 
[23]. This result was agreeing with the results obtained by Abdelbary et al., 
Formulations containing span 20 as surfactants show a lower entrapment efficiency 
comparatively to other surfactants this could be due to the lower HLB value of Span 20. 
This result was agreeing with the results obtained by Q. Lv et al [49]. 
HLB values of non ionic surfactants are Pluronic F68 (29.0), Tween 80 (15.0), Span 
20 (8.6). 
Hence the entrapment efficiency of various SLN stabilized with different nonionic 
surfactants decrease in the order of 
 Pluronic F68 > Tween 80 > span 20 
These results explained that the entrapment efficiency increases with increasing 
concentration of non ionic surfactants based on their hydrophilicity. Abdelbary et al 
developed the diazepam loaded solid lipid nanoparticles had the highest entrapment 
efficiency with poloxamer 188 than Tween 80 is consistent with these results [23]. 
 
Effect of lipid material on entrapment efficiency 
 It could be noted that for formulations prepared using either glyceryl 
monostearate or glyceryl monooleate as lipid matrix, there is a considerable difference 
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in the entrapment efficiency. For SLN formulations prepared with glyceryl 
monostearate (F1 –F9) and glyceryl monooleate (F10 – F18) as lipid matrix there is a 
noticeable influence on the entrapment efficiencies of prepared SLNs. This could be 
attributed to the difference in the solubility of the drug in the lipid (Muller et al 2000). 
The formulations prepared with glyceryl monostearate (F1 – F3) using tween 80 and 
formulations F4 and F5 using poloxamer 188 as stabilizer shows higher entrapment 
efficiency when compared to glyceryl monooleate. But for formulations F6 – F9 shows 
lower entrapment efficiency comparatively to formulation prepared with glyceryl 
monooleate (F15 – F18), this may be due to the crystallization of the lipid phase, which 
produces a partial expulsion of the drug on the particle surface. 
 
The order of entrapment efficiency of GMS SLN with non ionic surfactants was 
1. Poloxamer 188 (PF - 68) 
85.70% [GMS 6.0% + PF – 68 2.0%] > 84.13% [GMS 6.0% + PF – 68 1.5%] > 81.97% 
[GMS 6.0% + PF – 68 1.0%] 
 
2. Tween 80 (T - 80) 
81.22% [GMS 6.0% + T - 80 2.0%] > 80.06% [GMS 6.0% + T - 80 1.5%] > 78.72% 
[GMS 6.0% + T - 80 1.0%] 
 
3. Span 20 (S - 20) 
76.64% [GMS 6.0% + S - 20 2.0%] >74.85[GMS 6.0% + S - 20 1.5%] > 72.50% [GMS 
6.0% + S - 20 1.0%] 
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The order of entrapment efficiency of GMO SLN with non ionic surfactants was 
1. Poloxamer 188 (PF - 68) 
86.40% [GMO 6.0% + PF – 68 1.0%] > 84.48% [GMO 6.0% + PF – 68 1.5%] > 
79.82% [GMO 6.0% + PF – 68 2.0%] 
 
2. Tween 80 (T - 80) 
77.59% [GMO 6.0% + T - 80 2.0%] > 76.62% [GMO 6.0% + T - 80 1.5%] > 75.24% 
[GMO 6.0% + T - 80 1.0%] 
 
3. Span 20 (S - 20) 
82.71% [GMO 6.0% + S - 20 2.0%] >79.34% [GMO 6.0% + S - 20 1.5%] > 74.97% 
[GMO 6.0% + S - 20 1.0%] (Table - 4). 
The entrapment efficiency of the formulations (F16 – F18) prepared with GMO 
using span 20 as stabilizer shows higher percentage entrapment efficiency 
comparatively than formulations (F7 – F9) prepared with GMS using span 20 as 
stabilizer. This could be attributed to the melting point of the lipid; GMO has a lower 
melting point (32.5°C) when compared to GMS (56°C) (Zur muhlen et al.,). 
 
IN VITRO RELEASE STUDIES 
 The in vitro drug release studies of ramipril loaded solid lipid nanoparticles was 
done using dialysis bag diffusion technique in phosphate buffer saline PH 7.4. 
In vitro release from SLNs 
 In order to compare the drug release profile from the prepared SLN 
formulations, cumulative percentage drug release at 2 hours (Q2h) and cumulative 
percentage drug release at 12 hours (Q12h) were analyzed [23]. 
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 Generally, all SLN formulation showed significant slower release than ramipril 
solution (1mg/ml). This confirms that a sink condition for ramipril release was 
accomplished and the dialysis bag used in the dissolution procedure does not limit 
ramipril release.   
 For formulations F2, F3, F4, F5, F6, F8, F9, F10, F11, F12, F14, F15 and F18 a 
rapid release was observed at the initial 2 hours and released nearly 30% of the drug was 
released and at the end of 12 hours 54 – 81% of drug was released from the SLN, this is 
shown in the table 5 – 7 and in figures 9 - 16. After that a prolonged release was 
obtained due to the slow diffusion of the lipophilic drug from the lipid matrix 
(Abdelbary et al.,). The rapid release observed could be due to the drug enriched shell 
around the particles. Although the release rate of the SLN’s could be influenced by 
complex factors, it was reported that among the factors that contribute to the fast release 
are the large surface area, a high diffusion coefficient, low viscosity of the matrix, and a 
short diffusion distance for the drug (release from the outer surface region of the 
nanoparticle). 
 
Influence of lipid on drug release profiles of ramipril loaded SLN 
 By comparing the in vitro release results of SLN formulations prepared by GMS 
and GMO (F2 and F11, F3 and F12, F4 and F13, F5 and F14, F6 and F15, F8 and F17, 
F9 and F18) respectively. Formulations containing GMS as lipid matrix exhibited higher 
drug release extents than the formulations containing GMO as lipid matrix which shows 
a more sustained release. (Table – 5 - 7). 
 As mentioned above, GMO produces less ordered lipid crystals than GMS, 
leading to lower drug expulsion from the imperfect lattice, contributing to the prolonged 
release of the lipophilic drug (Fahmy et al.,). 
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 Moreover, GMO a lipid with lower melting point when compared to GMS.  Zur 
Muhlen et al., reported that lower melting point lipid can produce a controlled release 
from SLN. This is due to the presence of solid solution throughout the particle 
combined with the slow diffusion of drug from the lipid matrix.  
 
Influence of surfactants on drug release profiles of ramipril loaded SLN 
 The results revealed that all the formulation made from GMS as lipid matrix and 
from surfactants (F3 - Tween 80 2.0%, F6 - Poloxamer 188 2.0%, F9 - Span 20 2.0%) as 
stabilizer showed a higher drug release from ramipril loaded SLN, this showed that the 
increase in the concentration of the surfactant there is an increased the drug release from 
the SLN. This is confirmed by abdelbary et al.,[23].  
 But, this difference could not be attributed to the formulations [F12, F15 and 
F18] made from GMO using Tween 80 2.0%, Poloxamer 188 2.0% and Span 20 2.0% 
respectively. These formulations showed a decrease in the drug release on the increase 
of concentration of surfactant, this may be due to lower melting point of GMO than 
GMS. 
 These results revealed that higher concentration of Poloxamer 188 2.0% [F6] 
exhibit higher drug release, (Jawahar et al.,) while using GMS as lipid matrix. In all 
the formulations prepared by using both lipids (GMS and GMO) with Span 20 as 
surfactants shows higher retarded drug release. This may be due to the lower HLB value 
of Span 20 (8.6) than the other surfactants used as stabilizers Q. Lv et al [49]. 
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Comparison of In vitro drug release of ramipril loaded SLN with ramipril pure 
drug solution 
 The release of ramipril from SLN is much slower and controlled than the 
ramipril pure drug solution (1mg/ml). Ramipril showed a release of about 77% within 4 
hours. The sustained release profile of SLN was compared with pure drug solution and 
shown in table – 8 and figure - 18. 
 
PARTICLE SIZE ANALYSIS 
 The mean particle size and its distribution were measured by dynamic light 
scattering technique. Six formulations were selected, three each from two lipids (GMS – 
F3, F6, F9) and (GMO – F12, F15, F18) containing Tween 80, Poloxamer 188 and Span 
20 of similar concentration (2.0%) respectively.  
 Sizes of ramipril SLN of GMS and GMO with different non ionic surfactants 
(Tween 80, Poloxamer 188 and Span 20) were found to be in the range of 104 – 334 nm. 
The results are shown in table 9 and figure 18. The particle size distribution are shown 
in figure 19 – 22. 
 
Effect of different lipids on the particle size of ramipril SLN 
 Figure 18 shows the effect of different surfactants on the particle size 
distribution of ramipril SLN made of GMS and GMO. There is a significant difference 
in the size of the particles with change in lipids. Ramipril loaded SLN with GMS as 
lipid matrix results in larger particle size comparatively to Ramipril loaded SLN with 
GMO as lipid matrix for all type of surfactants. This phenomenon could be explained by 
melting point of the lipid, GMS has a higher melting point than GMO, which results in 
Chapter IX                                                                                       Results and Discussion 
 74
slower lipid recrystallization from the hot homogenized condition resulting in increase 
in particle size (Zur muhlen et al.,). 
 
Effect of different surfactants on the particle size of ramipril SLN 
 Figure shows the effect of different surfactants on the particle size distribution of 
ramipril SLN made of Tween 80, Poloxamer 188 and Span 20. 
There is a significant difference in the size of the particles with the change in the 
type of the surfactants. SLN dispersion prepared using Poloxamer 188 (2.0%) [F6 and 
F15] shows lower particle size than the other surfactants. This result could be attributed 
due to the higher molecular weight of Poloxamer 188 and higher HLB value when 
compared to Tween 80 and Span 20 (Muller et al.,).     
 Hence the particle size of various SLN stabilized with different nonionic 
surfactants increase in the order of 
 Poloxamer 188 > Tween 80 > span 20 
 
SCANNING ELECTRON MICROSCOPY (SEM) 
 The particle size, shape and surface morphology was evaluated using SEM. 
SEM photographs of ramipril loaded SLN of selected formulations [F3, F6, F9, F12, 
F15 and F18] was observed. In all the selected formulations, the particles were almost 
spherical and homogenous. The micrographs also confirmed that SLNs was less than 
400nm in size. The results showed that the ramipril loaded SLN particles have a 
spherical shape with smooth surface. This is shown in the figure 23 – 28. 
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FT - IR STUDIES 
 I.R studies were carried out to confirm the compatibility between the selected 
lipid, drug ramipril and SLN. The spectra obtained from the I.R studies are from 4400 
cm-1 to 450 cm-1. It was confirmed that there are no major shifting as well as no loss of 
functional peaks between the spectra of drug, lipid and drug loaded SLN (1743.98 cm-1, 
1654.04 cm-1, 1458.18 cm-1, 2931.34 cm-1). 
 
STABILITY OF RAMIPRIL LOADED SLN  
 The stability studies of all formulations of ramipril loaded SLN were 
carried out by storing at 40C (refrigeration temperature) and 250C + 20C [38]. 
The entrapment efficiency of the drug in the SLN dispersion was estimated 
immediately after the preparation and the results are shown in the table. The entrapment 
efficiency of the SLN dispersion, after every 15 days was estimated and the results are 
shown in the table – 10 and 11. 
 The results showed that the entrapment efficiency of all formulations 
showed only a slight decrease after 30 days. Hence increase in temperature and storage 
period decreases the entrapment efficiency of SLN dispersion irrespective of the lipids 
and emulsifiers used for formulations. The results showed that the entrapment efficiency 
of the SLN dispersion stored in 4°C was more when compared to SLN dispersion stored 
in 250C + 20C. Hence increase in temperature and storage period decreases the 
entrapment efficiency of SLN dispersion. Comparatively slightly high entrapment 
efficiency of drug was observed with SLN stored in refrigerated temperature. 
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CHAPTER X 
SUMMARY AND CONCLUSION 
¾ The purpose of this research was to prepare ramipril loaded solid lipid 
nanoparticles for controlled release of drug and a trial to improve the bioavailability. 
¾ Hot homogenization and ultrasound dispersion were employed to produce SLNs 
using biodegradable lipids and non ionic surfactants. 
¾ The formulated SLNs were characterized for entrapment efficiency, particle size 
and in vitro release studies in phosphate buffer saline PH 7.4. 
¾ The nanoparticle colloidal drug delivery system of ramipril prepared type of 
lipids and non ionic surfactants obtained better entrapment efficiency.  
¾ The better entrapment efficiency of SLNs was obtained with more hydrophilic 
surfactants (poloxamer 188) about 85.36% due to the higher HLB value of the 
surfactant. 
¾ The results revealed that the increase in the surfactant concentration increases 
the entrapment efficiency for all formulations and the percentage entrapment efficiency 
of various non ionic surfactants was observed in the order of Poloxamer 188 > Tween 
80 > Span 20. 
¾ The particle size of the formulated ramipril SLNs exhibited nanometer size 
range spherical shape particles. 
¾ The in vitro release studies revealed that the SLN formulations showed a 
prolonged drug release. 
¾ SEM analysis of the SLN dispersion showed the spherical shape of the 
nanoparticles. 
¾ Stability studies indicated that the entrapment efficiency of the SLN was not 
affected significantly in the refrigerated storage temperature. However there may be a 
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slight reduction in the entrapment efficiency of the SLN due to the drug expulsion from 
the crystal lattice. 
¾ The results of the IR studies proved that no interactions between the drug, lipid 
and formulations. 
It is concluded that the hot homogenization and ultrasound dispersion method, is 
a useful method for the successful incorporation of poorly water soluble drug ramipril 
with high entrapment efficiency. The prolonged release of the drug from the solid lipid 
nanoparticles suggests that the frequency of administration may be reduced. Further it 
may be presumed that if the nanometer range particles are obtained, the bioavailability 
may be increased. Hence we can conclude that solid lipid nanoparticles provide 
controlled release of drug and these systems are used as drug carriers for lipophilic 
drugs to enhance the bioavailability of poorly water soluble drugs through nanoparticle 
as a drug delivery system. 
 
 
 
 
 
   
   
     
  
 
 
 
 
 
 
 
 
 
 
 
 
SEM PHOTOGRAPHS 
 
Figure - 23 
  
 
                F3 - GMS 6% + Tween 80 2.0% 
 
 
 
 
Figure - 24 
 
 
F6 - GMS 6% + Poloxamar 188 2.0% 
 
 
Figure - 25 
 
 
 
F9 - GMS 6% + Span 20 2.0% 
 
 
 
 
 
Figure - 26 
 
 
F12 - GMO 6% + Tween 80 2.0% 
 
 
 
 
F15 - GMO 6% + Poloxamer 188 2.0% 
 
 
 
 
 
 
 
 
 
F18 - GMO 6% + Span 20 2.0% 
Table -2 
CALIBRATION CURVE OF RAMIPRIL IN 
DISTILLED WATER 
 
 
S.NO. CONCENTRATION (µg/ml) ABSORBANCE ± SD 
1 5 0.111 ± 0.0004 
2 10 0.235 ± 0.0008 
3 15 0.323 ± 0.0004 
4 20 0.45 ± 0.0008 
5 25 0.550 ± 0.0004    
6 30 0.676 ± 0.0008  
7 35 0.765 ± 0.0004 
8 40 0.873 ± 0.0004 
9 45 0.975 ± 0.0012 
10 50 1.075 ± 0.0008 
n = 3*                                                                       γ - 0.999291850 
 
                
 
 
Table -3 
CALIBRATION CURVE OF RAMIPRIL IN PHOSPHATE BUFFER 
SALINE PH 7.4 BUFFER 
 
S.No. CONCENTRATION (µg/ml) ABSORBANCE ± SD 
1 5 0.199 ± 0.0009  
2 10 0.380 ± 0.0004 
3 15 0.583 ± 0.0009 
4 20 0.775 ± 0.0031 
5 25 0.974 ± 0.0009 
6 30 1.172 ± 0.0010 
7 35 1.384 ± 0.0009 
8 40 1.571 ± 0.0012 
9 45 1.762 ± 0.0012 
10 50 1.965 ± 0.0012  
n = 3*                                                                    γ -  0.999938578                                     
 
 
 
 
 
 
 
 
 
 
 
Table -1 
FORMULATION OF RAMIPRIL LOADED SOLID LIPID NANOPARTICLES 
S.NO FORMULATION
COMPOSITION 
LIPID % W/V SURFACTANT % W/V 
1 F1 GMS 6.0 Tween 80 1.0 
2 F2 GMS 6.0 Tween 80 1.5 
3 F3 GMS 6.0 Tween 80 2.0 
4 F4 GMS 6.0 Poloxamer 188 1.0 
5 F5 GMS 6.0 Poloxamer 188 1.5 
6 F6 GMS 6.0 Poloxamer 188 2.0 
7 F7 GMS 6.0 Span 20 1.0 
8 F8 GMS 6.0 Span 20 1.5 
9 F9 GMS 6.0 Span 20 2.0 
10 F10 GMO 6.0 Tween 80 1.0 
11 F11 GMO 6.0 Tween 80 1.5 
12 F12 GMO 6.0 Tween 80 2.0 
13 F13 GMO 6.0 Poloxamer 188 1.0 
14 F14 GMO 6.0 Poloxamer 188 1.5 
15 F15 GMO 6.0 Poloxamer 188 2.0 
16 F16 GMO 6.0 Span 20 1.0 
17 F17 GMO 6.0 Span 20 1.5 
18 F18 GMO 6.0 Span 20 2.0 
GMS – Glyceryl monostearate, GMO – Glyceryl monooleate. 
Drug concentration used in each formulation kept as constant 5mg/5ml. 
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